Roche Receives FDA Priority Review for Enspryng in Thyroid Eye Disease – IL-6 Inhibitor Leverages Novel Recycling Technology for Second Indication
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the U.S. Food and Drug...
Drug
Huiyu Pharma Receives NMPA Clinical Trial Approval for HY-1016 Extended-Release Dienogest Injection – Novel Formulation Aims to Transform Endometriosis Treatment Adherence
Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced today that it has received clinical trial...
CSPC Innovation Launches Phase III Trial of SYS6010 ADC-PD-1 Combo in Resected NSCLC – Novel EGFR-Targeted Antibody-Drug Conjugate Enters Adjuvant Setting
CSPC Innovation Pharmaceutical Co., Ltd. (SHE: 300765) announced today the initiation and public registration of...
Sanofi Reports Positive Phase 3 Baby-COMET Results for Nexviazyme in Infantile-Onset Pompe Disease – ERT Shows 100% Survival and Ventilation-Free Outcomes at 52 Weeks
Sanofi S.A. (NASDAQ: SNY) announced today positive top-line results from the Baby-COMET Phase 3 study...
BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced today positive top-line results from...
Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) announced that the National Medical Products Administration (NMPA)...
AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx
AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, demonstrating...
Hua Medicine Completes Greater China Rollout as Dorzagliatin Gains Macau Approval – First-in-Class Glucokinase Activator Now Available Across All Chinese Territories
Hua Medicine (HKG: 2552) announced that the Pharmaceutical Administration Bureau of the Macau Special Administrative...
AbbVie’s SKYRIZI Wins FDA Approval for Pediatric Psoriasis, Expanding IL-23 Blocker to Children Six and Older
AbbVie (NYSE: ABBV) announced on June 26, 2026, that the U.S. Food and Drug Administration...
Akeso Biopharma Ships First Batch of Gumokimab for Psoriasis Following NMPA Approval
Akeso Biopharma (HKG: 9926) announced on June 26, 2026, that Qiyoukang (gumokimab, AK111) has completed...
Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use
Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines...
J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line
Johnson & Johnson (J&J, NYSE: JNJ) announced on June 26, 2026, that the Committee for...
Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China’s National Medical Products Administration (NMPA)...
Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...
Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorization...
Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon Canada announced the official commercial launch of...
AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six
AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has granted marketing authorization for...
Sanofi’s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia – Expanding Global Footprint Across Six Major Markets
Sanofi S.A. (NASDAQ: SNY) announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved...
Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody – Dual US-China Authorization for Hematological Malignancies
Mabwell Bioscience Co., Ltd. (HKG: 2493) announced that China’s National Medical Products Administration (NMPA) has...
Ab&B Bio-Tech Secures NMPA Clinical Trial Approval for mRNA Mpox Vaccine – First Dual-Approved Candidate Globally
Ab&B Bio-Tech Co., Ltd. (HKG: 2627) announced that China’s National Medical Products Administration (NMPA) has...